,,ii  #aaeth ,,congress  #b;d ,session  
,s4 #bece  ,,in ,,the ,,senate ,,of     
,,the ,,united ,,states  ,march #ab1    
#bjah ,mr4 ,durbin 7for himself1 ,mr4   
,kennedy1 ,mr4 ,grassley1 and ,mrs4     
,feinstein7 introduced the following    
bill2 which was read twice and referred 
to the ,committee on the ,judiciary  ,a 
,,bill  ,to amend the ,controlled       
,substances ,act to strengthen ,drug    
,enforcement ,administration discretion 
in setting opioid quotas4  #a4 ,short   
title  ,this ,act may be cited as the   
,opioid ,quota ,reform ,act4  #b4       
,strengthening considerations for ,,dea 
opioid quotas ,section #cjf of the      
,controlled ,substances ,act 7#ba       
,u4,s4,c4 #hbf7 is amended-- 7#a7 in the
 last sentence of subsection 7a71 by    
striking and not in terms of individual 
pharmaceutical dosage forms prepared    
from or containing such a controlled    
substance2 and  7#b7 by adding at the   
end the following3  7i7 7#a7 ,in fixing 
and adjusting production and            

manufacturing quotas under this section 
for fentanyl1 oxycodone1 hydrocodone1   
oxymorphone1 and hydromorphone1 the     
,attorney ,general shall consider the   
impact of the production and            
manufacturing quotas on overall public  
health and rates of diversion1 abuse1   
and overdose deaths related to these    
controlled substances in the ,united    
,states4 ,any of the considerations in  
this subsection or in subsection 7a7 may
 be used to determine changes to levels 
of such production and manufacturing    
quotas in a given year4  7#b7 7,a7 ,for 
any year in which the approved          
production quota for fentanyl1          
oxycodone1 hydrocodone1 oxymorphone1 or 
hydromorphone is higher than the        
approved production quota for the       
substance in the previous year1 the     
,attorney ,general shall include in its 
final order an explanation of why the   
public health benefits of increasing    
such quota outweigh the consequences of 
having an increased volume of such      

substance available for sale1 and       
potential diversion1 in the ,united     
,states4  7,b7 ,not later than #a year  
after the date of enactment of this     
subsection and every year thereafter1   
the ,attorney ,general shall provide to 
the ,caucus on ,international ,narcotics
 ,control1 ,committee on the ,judiciary1
 ,committee on ,health1 ,education1     
,labor1 and ,pensions1 and ,committee on
 ,appropriations of the ,senate and the 
,committee on the ,judiciary1 ,committee
 on ,energy and ,commerce1 and          
,committee on ,appropriations of the    
,house of ,representatives1 the         
following information with regard to    
each of the substances described in     
subparagraph 7,a73  7i7 ,an anonymized  
count of the total number of            
manufacturers issued individual         
manufacturing quotas that year for that 
substance4  7ii7 ,a count of how many   
such manufacturers were issued an       
approved manufacturing quota that was   
higher than the quota issued to that    

manufacturer for that substance in the  
previous year4  7#c7 ,not later than    
#ahj days after the date of enactment of
 this subsection1 the ,attorney ,general
 shall submit to ,congress a report on  
how the ,attorney ,general will ensure  
that the annual process of fixing and   
adjusting production and manufacturing  
quotas under this section takes into    
consideration--  7,a7 efforts to reduce 
the costs1 injuries1 and deaths         
associated with the diversion and abuse 
of prescription opioids and heroin1     
including changes in the accepted       
medical use of certain controlled       
substances2 and  7,b7 data collection   
and evaluation of the volume of         
controlled substances that are diverted 
and collected from approved drug        
collection receptacles1 mail-back       
programs1 and take-back events4  4